Carter Sherman

Like, this is not really his top issue.

He has flip-flopped on it a lot.

And so I can't imagine he really wants to swing a spotlight back onto it at this time.

The politics would not be good.

Oh, yeah, especially ahead of the midterms.

This is not something that I think the GOP really, really wants people to be focused on right now.

Thank you.

I really appreciate the sum up.

This is helpful.

I like being listened to like this.

What's the fourth?

OK, so the fourth thing is that the Trump administration has taken kind of a baby step to limiting abortion access.

And the FDA has agreed to review the safety of mifepristone.

Now, remember, mifepristone is safe.

That is not really something that is up for debate.

Nevertheless, the FDA, because it's reviewing it, could change the terms of access to mifepristone.

They could make it harder for abortion providers to mail it.

They could make it harder for abortion providers to access it.

We don't know what they're going to do and we don't know when they're going to do it.

Anti-abortion activists have actually gotten kind of mad over the FDA review because they feel like it's being slow walked.